KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,071,302 | -20.7% | 472,751 | 0.0% | 0.01% | -11.1% |
| Q2 2023 | $18,995,136 | -5.9% | 472,751 | 0.0% | 0.01% | -10.0% |
| Q1 2023 | $20,186,468 | -11.1% | 472,751 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $22,701,503 | +27.6% | 472,751 | -0.1% | 0.01% | +20.0% |
| Q3 2022 | $17,794,000 | +36.2% | 472,998 | +0.0% | 0.01% | +66.7% |
| Q2 2022 | $13,066,000 | -39.1% | 472,880 | +19.8% | 0.01% | -33.3% |
| Q1 2022 | $21,463,000 | -7.1% | 394,677 | -0.0% | 0.01% | +12.5% |
| Q4 2021 | $23,094,000 | +47.9% | 394,688 | +0.0% | 0.01% | +33.3% |
| Q3 2021 | $15,613,000 | -6.9% | 394,660 | -0.0% | 0.01% | 0.0% |
| Q2 2021 | $16,764,000 | +4.7% | 394,725 | +51.7% | 0.01% | -14.3% |
| Q1 2021 | $16,014,000 | -12.7% | 260,179 | +0.0% | 0.01% | -12.5% |
| Q4 2020 | $18,349,000 | – | 260,126 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |